Skye Bioscience, Revenue vs. Current Ratio
| SKYE Stock | USD 2.46 0.20 7.52% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.7 | 0.71 |
|
|
For Skye Bioscience, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Skye Bioscience, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Skye Bioscience, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Skye Bioscience,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Skye Bioscience, Common over time as well as its relative position and ranking within its peers.
Skye |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Skye Bioscience, Common Current Ratio vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Skye Bioscience,'s current stock value. Our valuation model uses many indicators to compare Skye Bioscience, value to that of its competitors to determine the firm's financial worth. Skye Bioscience, Common is currently under evaluation in revenue category among its peers. It is rated below average in current ratio category among its peers . At present, Skye Bioscience,'s Total Revenue is projected to stay steady based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Skye Bioscience, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Skye Revenue vs. Competition
Skye Bioscience, Common is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 226.15 Billion. Skye Bioscience, adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.
Skye Current Ratio vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Skye Bioscience, |
| = | null |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Skye Bioscience, |
| = | 0.91 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Skye Current Ratio Comparison
Skye Bioscience, is currently under evaluation in current ratio category among its peers.
Skye Bioscience, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Skye Bioscience,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Skye Bioscience, will eventually generate negative long term returns. The profitability progress is the general direction of Skye Bioscience,'s change in net profit over the period of time. It can combine multiple indicators of Skye Bioscience,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.7 M | -8.1 M | |
| Income Tax Expense | 3.6 K | 2.8 K | |
| Net Interest Income | -806.3 K | -846.6 K | |
| Operating Income | -13.7 M | -14.4 M | |
| Net Loss | -37.6 M | -35.8 M | |
| Income Before Tax | -37.6 M | -35.8 M | |
| Total Other Income Expense Net | -24 M | -22.8 M | |
| Net Loss | -37.6 M | -35.8 M | |
| Interest Income | 100 K | 105 K | |
| Change To Netincome | 695.2 K | 983 K | |
| Net Loss | (5.37) | (5.64) | |
| Income Quality | 0.37 | 0.39 | |
| Net Income Per E B T | 1.00 | 0.95 |
Skye Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Skye Bioscience,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Skye Bioscience, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Skye Bioscience,'s important profitability drivers and their relationship over time.
Use Skye Bioscience, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Skye Bioscience, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Skye Bioscience, will appreciate offsetting losses from the drop in the long position's value.Skye Bioscience, Pair Trading
Skye Bioscience, Common Pair Trading Analysis
The ability to find closely correlated positions to Skye Bioscience, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Skye Bioscience, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Skye Bioscience, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Skye Bioscience, Common to buy it.
The correlation of Skye Bioscience, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Skye Bioscience, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Skye Bioscience, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Skye Bioscience, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Skye Bioscience, position
In addition to having Skye Bioscience, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run EUR Crypto Assets Thematic Idea Now
EUR Crypto Assets
An experimental p2p digital currency that is accepted by many vendors in Euro. The EUR Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize EUR Crypto Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
To fully project Skye Bioscience,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Skye Bioscience, Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Skye Bioscience,'s income statement, its balance sheet, and the statement of cash flows.